| Literature DB >> 32276470 |
Alessio Metere1, Elisabetta Fabiani2, Maria Teresa Lonardo3, Domenico Giannotti4, Daniela Pace5, Laura Giacomelli1.
Abstract
Background andEntities:
Keywords: breast cancer; mastectomy; nipple-sparing mastectomy; nipple-sparing outcome
Mesh:
Year: 2020 PMID: 32276470 PMCID: PMC7230840 DOI: 10.3390/medicina56040166
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Representation of some characteristics of the analyzed population.
| Characteristics | Patients ( |
|---|---|
| 47.5 (range 22–76) | |
| 295 (33) vs. 599 (67) | |
| 733 (82) vs. 161 (18) | |
| 692 (77.4) vs. 202 (22.6) | |
| Invasive ductal carcinoma | 599 (67) |
| In situ ductal | 200 (22.4) |
| Invasive lobular carcinoma | 51 (5.7) |
| In situ lobular | 32 (3.6) |
| Tubular carcinoma | 5 (0.6) |
| Medullary carcinoma | 3 (0.3) |
| Mucinous carcinoma | 2 (0.2) |
| Invasive papillary carcinoma | 1 (0.1) |
| Metaplastic carcinoma | 1 (0.1) |
| ER+ | 779 (87.1) |
| ER− | 115 (12.9) |
| PgR+ | 729 (81.5) |
| PgR− | 165 (18.5) |
| HER2+ | 71 (8) |
| HER2− | 823 (92) |
| Ki67+ | 323 (36.1) (>20%) |
| Ki67− | 571 (63.9) (≤20%) |
| CT neoadjuvant | 215 (24) |
| CT adjuvant | 264 (29.5) |
| RT | 87 (9.7) |
| italic “S” vs. inframammary fold | 450 (50.3) vs. 317 (35.5) |
| radial vs. inframammary fold | 127 (14.2) vs. 317 (35.5) |
BMI—body mass index; ER—Estrogen Receptors; PgR—Progesterone Receptors; HER2—human epidermal growth factor receptor 2; CT—Chemotherapy; RT—Radiotherapy.
Statistical analysis of prognostic factors for complications.
| Variables | Early |
| Late |
|
|---|---|---|---|---|
| Adjuvant CT 1 | - | 1.76 (1.13–2.75) | 0.01 * | |
| Neoadjuvant CT | 1.25 (0.45–3.50) | 0.66 | 1.85 (0.82–4.20) | 0.14 |
| RT 1 | - | 1.22 (0.68–2.21) | 0.51 | |
| BMI (<30 vs. ≥30) | 0.85 (0.55–1.33) | 0.49 | 1.02 (0.97–1.10) | 0.37 |
| Age (<47 vs. ≥47) | 0.78 (0.53–1.15) | 0.22 | 1.14 (0.73–1.79) | 0.54 |
| Incision | ||||
| italic “S” vs. inframammary fold | 1.15 (0.78–1.71) | 0.48 | 1.34 (0.81–2.22) | 0.25 |
| radial vs. inframammary fold | 1.04 (0.60–1.80) | 0.88 | 1.31 (0.62–2.78) | 0.48 |
| Smoking | 1.36 (0.91–2.03) | 0.13 | 1.42 (0.87–2.33) | 0.16 |
1 Adjuvant CT and RT were administered one month later than surgery and consequently, they were considered as prognostic factors only for late complications. OR—odds ratio; CI—confidence interval. * statistically significant.
Global survival, disease-free survival, local relapse, and areola–nipple complex from meta-analysis in the literature.
| Author | NSM ( | Follow-up (Months) | Overall Survival (%) | Disease-Free Survival | Local Recurrence (%) | NAC |
|---|---|---|---|---|---|---|
| Adam et al. [ | 67 | 36 | 96.2 | 94.1 | 0 | 0 |
| Boneti et al. [ | 152 | 25.3 | - | - | 4.6 | - |
| Burdge et al. [ | 39 | 25.3 | 97.4 | - | 10.3 | 0 |
| Caruso et al. [ | 50 | 66 | 92 | 88 | 0 | 2 |
| Crowe et al. [ | 83 | 41 | 98.8 | 95.1 | 0 | 1.2 |
| Gerber et al. [ | 60 | 101 | 76.7 | - | 11.7 | 1.7 |
| Jensen et al. [ | 77 | 60.2 | 100 | 100 | 0 | 0 |
| Kim et al. [ | 152 | 60 | 97.1 | 89 | 2 | 1.3 |
| Nava et al. [ | 58 | 36 | 98.2 | 94.9 | 1.6 | 0 |
| Paepke et al. [ | 94 | 34 | 98.9 | 94.7 | 1.1 | 0 |
| Poruk et al. [ | 105 | 25.8 | 96.2 | 92.4 | 1.9 | 0 |
| Sacchini et al. [ | 68 | 24.6 | 98.5 | 95.6 | 2.9 | 0 |
| Shi et al. [ | 35 | 68 | 94.3 | 82.9 | 5.7 | 2.9 |
| Sood et al. [ | 76 | 15.7 | 98.7 | 91.9 | 7.9 | 1.3 |
| Tancredi et al. [ | 55 | 21.7 | 100 | 92.7 | 0 | 3.6 |
| Voltura et al. [ | 29 | 18 | 96.6 | 93.1 | 6.9 | 0 |
(A)
| Early Complications | Late Complications | ||
|---|---|---|---|
| Nipple–areola necrosis | 57 (6.4) | Capsular contracture | 199 (22.2) |
| Depigmentation | 28 (3.1) | Prosthesis dislocation | 73 (8.2) |
| Nipple necrosis | 25 (2.8) | Prosthesis extrusion | 34 (3.8) |
| Prothesis infection | 20 (2.2) | No complications | 588 (65.8) |
| Epidermolysis | 15 (1.7) | ||
| Skin flap necrosis | 5 (0.6) | ||
| No complications | 744 (83.2) |
(B)
| Local Relapses | Regional Relapses | Distant Relapses |
|---|---|---|
| 44 (4.9%) | 32 (3.6%) | 26 (2.9%) |